Clinical trials: Type 1 Diabetes, completed
Diabetes Mellitus, Type 2
A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.
To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.
- Trial name
- NCT05411965
- Testing
- BR3003(T), BR3003B(R1), BR3003C(R2)
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Advanced Solid Malignancies
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.
- Trial name
- STRONG (NCT03084471)
- Testing
- MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
- Where
- 79 sites in United States, Canada and 6 more
- Volunteers
- 867 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Bright 1 Bodies Weight Management Program
Physical inactivity occurs among 65% to 95% of youth with type 1 diabetes (T1D) and based upon limited evidence may contribute to the rapidly growing incidence of overweight among this population.
- Trial name
- B1B (NCT02768987)
- Testing
- Bright 1 Bodies
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Type1diabetes
Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes
The treatment regimen for type 1 diabetes is complex and demanding, and many adolescents have problems with adherence. The proposed study will pilot test a positive psychology intervention for adolescents with type 1 diabetes…
- Trial name
- NCT02984709
- Testing
- Positive Psychology Intervention, Education
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt University
Diabetes, Diabetes Mellitus, Type 1
A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerance, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NN1952 as tablets in healthy volunteers and subjects with type…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01028404
- Testing
- NN1952, insulin aspart
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
The Guardcontrol Trial: Study to Assess if Type 1 Diabetics Can Improve Using the Real-time Values of Guardian RT
The objective of the study is to determine whether patients with poor glycemic control can improve metabolic control using the real-time values of the Guardian® RT compared to conventional self-monitoring blood glucose…
- Trial name
- NCT00111228
- Testing
- Guardian RT, SMBG only
- Where
- 8 sites in France, Germany and 5 more
- Volunteers
- 162 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus Type 1 Pre-Existing, Pregnancy Related
Closed-Loop Insulin in Mothers With Type 1 Diabetes and Baby Feeding Practices
This study will is a parallel two-group randomized controlled trial that will use the MiniMed 670G hybrid closed-loop system's continuous glucose monitor (GCM) insulin pump and computer algorithm to deliver insulin when in "auto…
- Conditions
- Diabetes Mellitus Type 1 Pre-Existing, Pregnancy Related, Feeding Behavior, Infant Development
- Trial name
- CLIMB (NCT04420728)
- Testing
- Early auto-mode, Delayed auto mode
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Type 1 Diabetes Mellitus
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes…
- Trial name
- EDITION JUNIOR (NCT02735044)
- Testing
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Where
- 107 sites in United States, Argentina and 22 more
- Volunteers
- 463 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Flash-glucose Monitoring in Sub-optimally Controlled Type 1 Diabetes (FLASH-UK)
FreeStyle Libre (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days, and a hand-held reader which is designed to largely replace the recommended 4-10 painful…
- Trial name
- FLASH-UK (NCT03815006)
- Testing
- Free Style Libre 2
- Where
- 8 sites in United Kingdom
- Volunteers
- 156 people
- Sponsor
- Manchester University NHS Foundation Trust
Type 1 Diabetes
Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation
This study designed to assess changes in control of Type 1 Diabetes in pubertal adolescents over a two year period. There are two arms/substudies, the first being a longitudinal randomized controlled trial and the second an…
- Trial name
- AP APPLE (NCT04510506)
- Testing
- Artificial Pancreas (AP)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Virginia
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Despite the fact that the majority of the patients with limited disease SCLC will respond very well to the standard treatment, a great proportion will relapse within 12 - 24 months.
- Trial name
- STIMULI (NCT02046733)
- Testing
- Ipilimumab, Nivolumab
- Where
- 61 sites in Australia, Belgium and 6 more
- Volunteers
- 222 people
- Sponsor
- ETOP IBCSG Partners Foundation
Diabetes, Diabetes Mellitus, Type 1
A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes
The aim of the study is to compare the pharmacokinetics (i.e. the course of the blood concentrations of the administered trial drug) of faster-acting insulin aspart (faster aspart), and the currently marketed formulation of…
- Trial name
- NCT03215498
- Testing
- Faster-acting insulin aspart, Insulin aspart
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)
The Diabetes Prevention Trial of Type 1 (DPT-1) was a multicenter randomized, controlled clinical trial designed to determine whether it is possible to delay or prevent the clinical onset of type 1 diabetes through daily doses of…
- Trial name
- DPT-1 (NCT00004984)
- Testing
- Parenteral Insulin, Close Observation, Oral Insulin
- Where
- 15 sites in United States, Canada
- Volunteers
- 711 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Insulin-Dependent
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
The objective of this clinical trial is to investigate whether ladarixin has sufficient activity (preservation of β-cell function and slow-down of the progression of T1D) to warrant its further development (proof of concept…
- Trial name
- NCT02814838
- Testing
- Ladarixin
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 76 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Implementing Continuous Glucose Monitoring in Primary Care for Patients With Diabetes
The overarching goal of this study is to decrease disparities and increase access to continuous glucose monitoring (CGM) for patients with diabetes, regardless of where people receive their diabetes care.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Continuous Glucose Monitoring
- Trial name
- PREPARE4CGM (NCT05336214)
- Testing
- Virtual CGM initiation service, Online educational module on CGM, Practice facilitation
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes Mellitus
Diabetes Control and Complications Trial (DCCT)
Background. Long-term microvascular and neurologic complications cause major morbidity and mortality in patients with insulin-dependent diabetes mellitus (IDDM).
- Trial name
- NCT00360815
- Testing
- Insulin
- Where
- 38 sites in United States, Canada
- Volunteers
- 1,441 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2, Insulin Resistance
New Frontiers on Bariatric Surgical Procedures: Classical Bypass for Type-2 Diabetic Patients With Obesity Grade I
Bariatric surgery leads to remission of type 2 diabetes in morbid obese patients in 80% (Roux-en-Y gastric bypass)to 90% (biliopancreatic diversion and duodenal switch) of cases.
- Conditions
- Diabetes Mellitus, Type 2, Insulin Resistance, Obesity
- Trial name
- NCT00566189
- Testing
- Roux-en-Y Bypass Gastroplasty
- Where
- Brazil
- Volunteers
- 36 people
- Sponsor
- University of Campinas, Brazil
Diabetes
Evaluation of Cissus Verticillata L. Infusion in Controlling Type 2 Diabetes
The purpose of this study was to investigate whether the infusion of a medicinal plant (Cissus verticillata L.) would be effective in reducing glucose levels in blood and saliva of type 2 Diabetes patients.
- Trial name
- NCT01145534
- Testing
- glibenclamide, medicinal plant infusion
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Federal University of Paraíba
diabète de Type 1
Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesteryl Ester Transfer Protein in Type-1 Diabetes Patients
In type-1 diabetes patients, bad cholesterol tends to accumulate because apoC1 function is slowed down. ApoC1 is a protein whose role is to diminish the activity of CETP, another protein that regulates cholesterol transfer in the…
- Trial name
- ApoC1 (NCT02816099)
- Testing
- Prise de sang
- Where
- 2 sites in France
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.